This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bovie Medical Corporation Appoints Jeff Rencher As Vice President Sales And Marketing For Surgical Products

Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the appointment of Jeff Rencher as vice president of sales and marketing for surgical products. Mr. Rencher joins Bovie with over 16 years of medical products sales experience. He is skilled in hiring and managing direct and independent sales representatives for both new and established medical products. In the past, Mr. Rencher has also been responsible for advertising, forecasting, marketing and trade shows for surgical and non-surgical medical products.

Andrew Makrides, president of Bovie, stated, “Jeff’s vast experience in increasing medical product sales through building direct and indirect sales teams will be a valuable addition to our management team. ”

An employment agreement with Mr. Rencher was entered into on June 25, 2010, and as part thereof, he was awarded a restricted non-qualified stock option for an aggregate of 30,000 shares of common stock, exercisable at $6 per share. The option has a ten year term and will vest upon the achievement of key sales objectives. This press release is issued in accordance with the exemption afforded under Section 711(a) of the NYSE AMEX Company Guide which exempts certain stock option grants made as an inducement to employment from the stockholder approval requirement.

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.

Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BVX $3.19 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs